Puik Jisce R, Le Chung, Kazemier Geert, Oprea-Lager Daniela E, Swijnenburg Rutger-Jan, Giovannetti Elisa, Griffioen Arjan W, Huijbers Elisabeth Jm
Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Surgery, De Boelelaan 1117, Amsterdam, the Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands.
Angiogenesis Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Crit Rev Oncol Hematol. 2025 Jan;205:104556. doi: 10.1016/j.critrevonc.2024.104556. Epub 2024 Nov 17.
Prostate-specific membrane antigen (PSMA) is one of the few biomarkers which has been successfully translated to the clinic as theranostic biomarker for patients with prostate cancer. In the context of prostate cancer, PSMA is overexpressed on the cell membrane of tumor cells, making it a viable target for interventions with urea-based small molecule inhibitors or antibodies conjugated to radioactive isotopes. Interestingly, in several non-prostatic cancers, expression of PSMA appears to be associated with the tumor neovasculature. This offers novel therapeutic opportunities for treatments targeting the vasculature in non-prostatic cancers. In this review, we discuss PSMA and its potential as target for vasculature-directed therapeutic approaches, including radioligand therapy, fusion protein vaccination and CAR T-cell therapy.
前列腺特异性膜抗原（PSMA）是少数已成功转化为临床应用的生物标志物之一，可作为前列腺癌患者的治疗诊断生物标志物。在前列腺癌的背景下，PSMA在肿瘤细胞膜上过度表达，这使其成为基于尿素的小分子抑制剂或与放射性同位素偶联的抗体进行干预的可行靶点。有趣的是，在几种非前列腺癌中，PSMA的表达似乎与肿瘤新血管形成有关。这为针对非前列腺癌血管系统的治疗提供了新的治疗机会。在这篇综述中，我们讨论了PSMA及其作为血管靶向治疗方法靶点的潜力，包括放射性配体疗法、融合蛋白疫苗接种和嵌合抗原受体T细胞疗法。
